PTK 2015 Banner 
2015 Peptalk M Banner 

Pipeline One Icon Pipeline One Header 

Cambridge Healthtech Institute’s 11th Annual
Recombinant Protein Therapeutics
Fusion Proteins and Beyond
January 19-20, 2015

The customizable functionality of fusion protein therapeutics creates advantages over antibody-based therapies by combining modular building blocks that can reach targets not accessible to antibodies. Additional advantages include lower patient dosing, reduced production costs and improved product homogeneity. The Recombinant Protein Therapeutics conference explores the varying constructs and “designs” of fusion protein molecules, and discloses how they are being engineered to form more efficacious therapeutics that offer specificity with enhanced stability and longer half life. Experts present case studies from R&D through clinical data and share the results they have achieved.

Preliminary Agenda 



Roche's Strategies to Discover, Design, Develop, and Deliver New Innovative Therapeutic Biologics 

Ralf Schumacher, Ph.D., Site Head, Large Molecule Research Penzberg; pRED Center Manager, Roche Diagnostics GmbH  

Unravelling the Molecular Basis of Host Cell Specific Glycosylation and Species Specific Pharmacokinetics  

Catherine Huntington, Ph.D., Research Scientist II, Antibody Discovery and Protein Engineering (ADPE), MedImmune, LLC 


A Neuroprotective Brain-Penetrating Endopeptidase Fusion Protein Ameliorates Alzheimer Disease Pathology and Restores Neurogenesis  

Eliezer Masliah, M.D., Professor, Neuroscience and Pathology, University of California, San Diego  

Novel Human Resistant Mutant that Acts as Antagonist Reduced Body Weight Gain and Restored Insulin Responsiveness in Mice Fed High Fat Diet  

Arieh Gertler, Ph.D., CEO, Protein Laboratories Rehovot; Professor-Emeritus and Head of Research Team, Biochemistry, The Hebrew University of Jerusalem 


Late Stage Development of a Chimeric Antibody 

Manfred Schuster, Ph.D., COO, Apeiron Biologics AG 

A Recombinant Immunotoxin for Cancer Treatment with Low Immunogenicity by Identification and Silencing of Human T Cell Epitopes 

Ronit Mazor, Ph.D., Research Fellow, Lab for Molecular Biology (LMB), NCI/NIH  


A Bi-Functional Antibody-Receptor Domain Fusion Protein Simultaneously Targeting IGF-IR and VEGF for Degradation  

Yang Shen, Ph.D., Director, Antibody Technology; Research Advisor, Antibody Engineering, ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company  

A Novel Glycoenginereed Bispecific Antibody Format for Targeted Inhibition of EGFR and IGF-1R Demonstrating Unique Molecular Properties  

Juergen Schanzer, Ph.D., Principal Scientist, Discovery Oncology, Roche Diagnostics GmbH 


Enhancing Stability of the Therapeutic Enzyme L-Asparaginase by Biocompatible Nanoparticles  

Manfred Konrad, Ph.D., Research Director, Enzyme Biochemistry, Max Planck Institute for Biophysical Chemistry 

Engineered Affibody Molecules in Multiple Formats for Targeted Therapy 

Fredrik Frejd, Ph.D., Vice President and CSO, Affibody AB 

DeBouganin Fusion Proteins: A "Fit for Purpose" ADC Drug Design  

Glen C. MacDonald, Ph.D., CSO, Viventia Bio, Inc.  

Manufacturing of Half-Life Extended Fusion Proteins: Current Trends and Challenges 

Stefan Schmidt, Ph.D., Vice President, DSP, Rentschler Biotechnology